Fra ASH:
-
Fra ASH:
Identifying the Worst of the Worst and How Best to Treat Them
Mark G. Frattini, MD, PhD
December 6, 2010In patients with CLL, Dr. Stephan Stilgenbauer from the University of Ulm in Ulm, Germany, described the ultra high-risk group as those with an expected overall survival of less than two to three years, patients with a chromosome 17p deletion or sole p53 mutation without 17p deletion, patients who are purine analog (i.e., fludarabine or pentostatin) refractory, and lastly those with only a 24- to 36-month remission duration following intensive therapy (e.g., FCR-fludarabine, cyclophosphamide, and rituximab). He stressed the need to treat these patients first-line on a clinical trial with novel agents. In addition, a consolidation strategy including either reduced-intensity allogeneic stem cell transplantation or clinical trial with novel agents should be considered depending on patient age and performance status. In the absence of a clinical trial with novel agents, immunotherapy with ofatumumab or alemtuzumab or other chemoimmunotherapy could be used.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind